Marie-Christine Daniel, PhD

Home Research Research Grants Program Grants Awarded All Grant Recipients Marie-Christine Daniel, PhD

Grantee: Marie-Christine Daniel, PhD

Institution: University of Maryland, Baltimore County
Research Project: Multifunctional Nanovectors for Pancreatic Cancer Therapy
Award: 2008 Constance Williams – Pancreatic Cancer Action Network – AACR
Career Development Award
Award Period: July 1, 2008 – June 30, 2010
Amount: $100,000

Click here to download Dr. Daniel’s Grant Snapshot
(pdf).

Biographical Highlights
Dr. Daniel is an Assistant Professor in the Department of Chemistry and Biochemistry at the University of Maryland, Baltimore County. She received her PhD in Chemistry at the University of Bordeau 1 in France, where she also pursued a teaching fellowship and became a research and teaching associate. Her postdoctoral training was conducted at Tokyo University in Japan and Indiana University in Bloomington. After losing her mother to a rare form of cancer, Dr. Daniel chose to devote her research to this field. Struck by the aggressiveness of pancreatic cancer and its very low survival rate, she decided to contribute to efforts to improve treatment of this highly aggressive disease.

Project Overview
This project focuses on the use of nanotechnology in pancreatic cancer therapeutics. Nanocarriers are much smaller than cells and have a size comparable to biological entities such as proteins or viruses. Among other properties, this confers upon them distinct advantages when used in treatment: they increase the blood circulation time compared to small drugs, provide protection of active agents against enzymatic or environmental degradation, and allow a combination of several different agents. Nanovectors are in general composed of three parts: a core constituent material, a therapeutic and/or imaging payload, and some biological surface modifiers that enable tumor targeting of the nanoparticle dispersion.

The objective of this project is to prepare nanoparticles that combine multiple agents and to test their effectiveness against transformed pancreatic cell lines. The nanovectors that will be prepared will combine gemcitabine, which is currently the standard chemotherapeutic for pancreatic cancer, and anti-RON antibodies that are expected to reinforce the cytotoxicity of gemcitabine. Upon the preferential entry of a nanovector into a cell, a very large quantity of the therapeutic agents will be delivered. This targeted combination therapy is predicted to allow for a dramatic enhancement in potency and efficacy in pancreatic cancer treatment along with a decrease in the side effects. In vitro (laboratory) testing of these nanovectors will be performed.

 

Wage Hope With Us

Join us to double pancreatic cancer survival by 2020.





shop purple logo

Gear, apparel, accessories and more to show off your purple pride.


Shop Now 

©2018 Pancreatic Cancer Action Network. All rights reserved. Terms of Use | Privacy Policy


Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision Promise℠ and Demand Better For Patients. For Survival.℠ are the trademarks of the Pancreatic Cancer Action Network, Inc.


The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.